Ranbaxy Labs launches cholesterol lowering drug in German market

06 Mar 2012 Evaluate

Ranbaxy Laboratories’ German subsidiary - Basics Gmbh in Leverkusen, has launched Atorvastatin basics (10/20/40/80 mg), a generic version of the cholesterol lowering drug Sortis, in the German market.

The company, pursuant to a settlement agreement with Pfizer, has obtained the rights to an early entry of Atorvastatin in the German market. Pfizer’s patent for Sortis expires in Germany on May 7, 2012. Further, Basics’ affiliates in Germany, Daiichi Sankyo Deutschland Gmbh, are expected to assist the company in the launch.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×